InMode Ltd v. BTL Industries Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: InMode Ltd. (Israel)
  • Defendant: BTL Industries, Inc. d/b/a BTL Aesthetics (Delaware)
  • Plaintiff’s Counsel: Venable LLP
• Case Identification: 2:23-cv-08583, C.D. Cal., 05/31/2024
• Venue Allegations: Plaintiff alleges venue is proper in the Central District of California because Defendant operates a "regular and established place of business," its Beverly Hills "Body Boutique," within the district, from which it conducts sales, promotions, and training related to the accused products.
• Core Dispute: Plaintiff alleges that Defendant’s radiofrequency-based vaginal rejuvenation devices and associated treatment methods infringe a patent related to non-invasive tissue remodeling.
• Technical Context: The technology concerns medical aesthetic devices that use radiofrequency energy to heat subcutaneous tissue, causing collagen contraction and stimulating new collagen growth to tighten tissue, in this case within the female genitalia.
• Key Procedural History: The complaint alleges Defendant was aware of the patent-in-suit due to a prior infringement lawsuit filed by the patent’s previous owner, Viveve, Inc., against a market competitor, ThermiGen, LLC. This prior litigation is cited as a basis for Plaintiff’s willful infringement claims.

Case Timeline

Date	Event
2006-02-07	U.S. Patent No. 8,961,511 Priority Date
2015-02-24	U.S. Patent No. 8,961,511 Issued
2017-01-01	Accused UltraFemme 360 Product Launched (approximate)
2022-01-01	Accused EmFemme 360 Product Launched (approximate)
2024-05-31	First Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,961,511 - “Vaginal Remodeling Device And Methods”

The patent, issued February 24, 2015, is referred to as the “’511 Patent”.

The Invention Explained

• Problem Addressed: The patent addresses the loosening of vaginal and surrounding tissues that can occur after childbirth, which may lead to medical issues and decreased sexual pleasure (’511 Patent, col. 1:62-2:9). The patent notes that surgical options to address this are often unpopular due to the risks associated with invasive procedures in a sensitive area, such as scarring (’511 Patent, col. 2:9-16).
• The Patented Solution: The invention is a non-invasive method and apparatus for remodeling and tightening genital tissue by applying radiant energy (such as radiofrequency) to heat targeted connective tissue beneath the surface (’511 Patent, abstract). A key feature is the simultaneous cooling of the surface mucosal epithelium, which protects it from heat damage while allowing energy to penetrate to the underlying target tissue (’511 Patent, abstract; ’511 Patent, col. 2:53-3:7). This process creates a “reverse thermal gradient,” heating the deeper collagen-rich layers to cause tightening while keeping the surface cool (’511 Patent, col. 4:8-14).
• Technical Importance: This technology offers a non-surgical alternative for aesthetic tissue tightening, potentially reducing the risks, recovery time, and patient reluctance associated with invasive procedures (Compl. ¶52).

Key Claims at a Glance

• The complaint asserts independent claims 1, 33, 35, and 41 (Compl. ¶7).
• Independent Claim 1:
  • A method for remodeling a therapeutic zone within a target tissue, the target tissue comprising tissue underlying an epithelium of female genital tissue comprising at least one of vulva, introitus and vagina tissue,
  • the method comprising: heating the target tissue, and
  • remodeling the therapeutic zone of target tissue,
  • wherein the heating includes heating a portion of the vagina extending from the introitus inwardly to a location from 1 cm to 3.5 cm in from the introitus.
• The complaint states it is asserting "at least" claims 1, 33, 35, and 41, which may suggest an intent to assert dependent claims later (Compl. ¶7).

III. The Accused Instrumentality

Product Identification

Defendant BTL’s UltraFemme 360 and EmFemme 360 products and the corresponding treatment methods (the "Accused Products") (Compl. ¶11).

Functionality and Market Context

• The complaint alleges the Accused Products are used to provide "non-invasive, radiofrequency vaginal rejuvenation treatments" (Compl. ¶56). They allegedly function by "homogeneously deliver[ing] volumetric heating throughout the treated area" to achieve a "fast and uniform treatment" (Compl. ¶56). The treatments are described as using heat to stimulate "new collagen formation" in the vaginal introitus and canal (Compl. ¶57).
• The complaint provides a screenshot from BTL’s website showing a search tool for locating healthcare providers in the Central District of California who offer these treatments, suggesting their use and availability in the market (Compl. ¶9).

IV. Analysis of Infringement Allegations

The complaint references a non-limiting claim chart in Exhibit 23, but this exhibit was not attached to the publicly filed complaint document (Compl. ¶61). The narrative infringement allegations are summarized below.

The complaint alleges that the Accused Products and associated methods practice the claimed invention (Compl. ¶61). The core of the infringement theory is that BTL's devices, when used for vaginal rejuvenation, perform the steps of the asserted method claims (Compl. ¶¶56-57). Specifically, the complaint alleges the Accused Products are "radiofrequency skin-tightening device[s]" that "heat[ing] the vaginal introitus and canal to stimulate new collagen formation" (Compl. ¶57). This functionality is alleged to correspond to the "heating the target tissue" and "remodeling the therapeutic zone" limitations of the asserted claims (’511 Patent, claim 1).

• Identified Points of Contention:
  • Factual Question: A central factual dispute may concern whether the Accused Products are used to treat the specific anatomical region defined in claim 1: "a portion of the vagina extending from the introitus inwardly to a location from 1 cm to 3.5 cm." The complaint does not provide specific details on the exact location or depth of treatment performed by the Accused Products.
  • Scope Question: The case may turn on how the court construes "remodeling the therapeutic zone." The question will be whether the general volumetric heating and collagen stimulation alleged to be performed by the Accused Products meet the specific requirements of this term as defined by the patent’s specification.

V. Key Claim Terms for Construction

• The Term: "remodeling the therapeutic zone" (’511 Patent, claim 1)
• Context and Importance: This term defines the ultimate outcome of the claimed method. Its construction will be critical to determining infringement, as the parties will likely dispute what specific physiological change constitutes "remodeling." Practitioners may focus on this term because the accused devices are alleged to provide general "volumetric heating" (Compl. ¶56), and the dispute will be whether this general effect satisfies the more specific "remodeling" required by the claim.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification suggests remodeling can result from multiple biological processes, stating it "may include heat-denaturing collagen" or may occur "substantially after the heating has occurred... as remodeling comprises biological healing responses to the stress of heating" including "the deposition of new collagen" (’511 Patent, col. 4:58-5:2). This could support a broader definition covering general tissue tightening over time.
  • Evidence for a Narrower Interpretation: The abstract links remodeling directly to the effect of the applied heat, which is "to remodel genital tissue by tightening it" as a "consequence of thermal denaturation of collagen" (’511 Patent, abstract). This language could support a narrower construction requiring immediate, heat-induced collagen contraction.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that BTL induces infringement by knowingly providing "literature, instructional videos, training guides, user manuals and other instructional materials" as well as "demonstrations and clinical trainings" that encourage and instruct third-party healthcare providers on how to use the Accused Products in an infringing manner (Compl. ¶¶71-72). Contributory infringement is alleged on the basis that the Accused Products are specially made for this infringing use and are not staple articles suitable for substantial non-infringing use (Compl. ¶¶75, 77).
• Willful Infringement: Willfulness is alleged based on BTL’s purported pre-suit knowledge of the ’511 Patent (Compl. ¶65). The complaint contends that BTL, as a competitor in the aesthetic healthcare market, knew or should have known about the patent from a prior lawsuit filed by the patent's original assignee, Viveve, against another competitor, ThermiGen (Compl. ¶¶62-63). The complaint also alleges willful blindness and post-suit knowledge from the filing of the complaint itself (Compl. ¶62; Compl. ¶63).

VII. Analyst’s Conclusion: Key Questions for the Case

• A central issue will be one of factual proof: Can InMode demonstrate that the standard treatment protocols for BTL's Accused Products involve heating the specific anatomical region recited in claim 1, namely the vaginal tissue "extending from the introitus inwardly to a location from 1 cm to 3.5 cm"?
• The case will also involve a key claim construction dispute: Does the term "remodeling," as used in the patent, require a specific, measurable biological effect like thermal collagen denaturation, or can it be satisfied by the more general "volumetric heating" and subsequent tissue tightening alleged to be performed by the accused devices?
• A critical evidentiary question for willfulness will be whether InMode can establish that BTL had actual pre-suit knowledge of the ’511 Patent and its relevance, likely focusing on what BTL knew about the prior litigation between its competitors, Viveve and ThermiGen.